01491nas a2200493   4500000000100000000000100001008004100002260001200043653001600055653001800071653002000089653002400109653002300133653002800156653001200184100002400196700001600220700001900236700001600255700001500271700001900286700002100305700002100326700001900347700001600366700002100382700001700403700002000420700001900440700002100459700001800480700001600498700001600514700002500530700002300555700001500578700001900593245011100612856005500723300001200778490000700790520018600797022001400983       2025                            d  c2025-0610abiomedicine10aBiotechnology10aCancer Research10aMedicinal Chemistry10aMolecular medicine10aPharmacology/Toxicology10ageneral1 aAndrew S. Robertson1 aNahid Latif1 aImein Bousnina1 aDonna Boyce1 aKevin Carl1 aSean P. Curtis1 aJennifer Dudinak1 aCarlos O. Garner1 aMichael Garvin1 aSabine Luik1 aKoen Nauwelaerts1 aEddie Reilly1 aMichelle Rohrer1 aKatrin Rupalla1 aJacintha Shenton1 aJerry Stewart1 aMark Taisey1 aAxel Vicart1 aRaymond C. Votzmeyer1 aMatthew P. Wagoner1 aMax Wegner1 aKathy Williams00aAccelerating adoption of new approach methodologies in regulatory decision making: an industry perspective  uhttps://www.nature.com/articles/d41573-025-00038-6  a401-4020 v243 aClear and harmonized regulatory guidelines are needed to realize the potential of new approach methodologies for improving the predictivity of nonclinical drug candidate assessment.  a1474-1784